The company has begun expansion efforts for its process-development capabilities and laboratory infrastructure.
On April 24, 2018, contract development and manufacturing organization (CDMO) Avid Bioservices provided an update on its ongoing efforts to expand its process-development capabilities and laboratory space within its Orange County, CA, CDMO campus.
The company has begun expanding its total available process-development laboratory space to more than 6,000 square feet, upgrading the infrastructure and equipment within its existing process development laboratories, and implementing new technologies and equipment designed to facilitate efficient, high-throughput development of innovative upstream and downstream manufacturing processes.
According to Avid, the company is strategically conducting this work in phases to avoid disruption to current customer programs, with the first new laboratories expected to be operational during the third quarter of 2018. The expansion is expected to directly improve the company's cell line development capabilities, supporting the ongoing evaluation and optimization of the its new Chinese hamster ovary (CHO)-based expression system.
Recently, the company has signed new agreements with three additional undisclosed international drug development companies, for which Avid will provide process-development and manufacturing services to support the advancement of each company's novel biologic candidate into clinical development. The drug candidates involved in these agreements are being developed for application in certain cell therapy, respiratory, and oncology indications. Avid states that it has already started work on each of these projects. With these recent agreements, the company has now executed master service agreements with four new clients in calendar 2018, as compared with four similar agreements during the entire 2017 calendar year, as stated by the company.
Source: Avid Bioservices
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.